Show results for
Refine by
Disease Modeling Suppliers Serving Malta
64 companies found
based inLeiden, NETHERLANDS
A leading pioneer in leveraging iPSC innovation for drug discovery. The catalyst with the requisite iPSC know-how and experience to empower innovators in drug discovery to advance their science relentlessly, consistently and efficiently. For the ...
Vascular endothelial cells are involved in multiple processess including blood flow, vascular permeability or angiogenesis. Our team can manufacture endothelial cells from the iPSC line that best fits your project with a controlled and scalable ...
based inCambridge, UNITED KINGDOM
We’re driven by the shared purpose of breaking new ground in the discovery of new treatments for rare diseases. Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to ...
Our Rare Treatment Accelerator helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to ...
based inNavi Mumbai, INDIA
Yashraj Biotech Limited manufactures a wide range of high pure biomarkers in the form of native and recombinant proteins that are used by the diagnostic industry as controls, calibrators and immunogens. YBL has been the preferred partner of most of ...
Neural Progenitor Cells (NPCs) are multipotent cells derived from iPSCs that are self-renewing and have the potential to differentiate into various neuronal lineages. This makes them very attractive for in vitro patient-specific ...
based inLancaster, CALIFORNIA (USA)
Simulations Plus provides cutting-edge software solutions and consulting services designed to enhance drug discovery, clinical development, and regulatory submission processes. With over 25 years of experience, the company has established itself as ...
based inEugene, OREGON (USA)
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
BlueWillow’s vaccine technology incorporates nano-scale droplets that are manufactured at an average size of 400–500 nanometers to deliver and adjuvant a broad spectrum of ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
based inDiepenbeek, BELGIUM
Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug ...
In vitro and in vivo methods to provide a study setup that thoroughly determines safety and efficacy. ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
15(R)-Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and a lipid-derived lipoxin-type specialized pro-resolving mediator (SPM) that plays a role in promoting inflammation resolution and regulating immune cell function. 15(R)-Lipoxin A4 can improve ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
In vitro retinal disease modelling for retinal therapy. Newcells offers a fast and reliable in vitro safety and efficacy service for the evaluation of novel compounds for retinal therapy using complex human retinal ...
based inShirley, NEW YORK (USA)
Creative Bioarray is a leading customer-centered biotechnology company and a pioneer with the latest technology of cell patterning. Creative Bioarray has an experienced expert team and is committed to providing comprehensive services and customized ...
GLP studies are done only for development compounds being prepared for clinical trials. Creative Bioarray has conducted in vivo testing for cardiovascular disease using in vivo models for both side-effect profiling ...
based inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
This module is the result of more than 20 years of investment and experience that are the cornerstone of Oncodesign’s international reputation. In PREDICT® , you have access to perfect knowledge of reference models in ...
based inEschborn, GERMANY
When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and ...
Identify the biomarkers best suited for your needs: Diagnose rare or ambiguous diseases, Group patients by endotype response for prognosis, Assess disease etiology to determine responsive patient group ...
based inSan Diego, CALIFORNIA (USA)
A San Diego based biotech company that's leading computational metabolomics for Natural Product Drug Discovery. Over the last decade and working with experts and local communities, Sirenas has sustainably and ethically built one of the largest and ...
The Global Leader in the Discovery of Natural Product Chemistry for Healthcare. Sirenas prides itself on being at the forefront of computational metabolomics for chemical discovery. Our deep experience and historical productivity indicate that ...
based inOceanside, CALIFORNIA (USA)
Eidogen-Sertanty is dedicated to improving health, medicine, and general well-being. For the last 20-years, Eidogen-Sertanty has helped to expedite the discovery and development of many new, safer medicines through collaborative project team ...
based inRostock, GERMANY
Since 2006, CENTOGENE has helped physicians diagnose thousands of rare disease patients around the world. A quick and accurate diagnosis can end an odyssey of medical tests and visits to multiple medical specialists. It also helps physicians better ...
We work with partners to develop new disease models and new biomarkers of disease. We can also use our disease models to identify new drug targets and screen ...
based inSan Francisco, CALIFORNIA (USA)
Tempo Bioscience, Inc (Tempo) develops human stem cells (human iPSC technology) based cell models and biosensor enabling technologies for preclinical drug discovery & development, biobanking, in vitro diagnostics, and biomarker development. Our ...
based inPhiladelphia, PENNSYLVANIA (USA)
Allevi creates tools and solutions to design, engineer and build with life. Our 3D bioprinters and bioinks are used around the world to find solutions to humanity’s most difficult problems – to cure disease, to test novel drugs, and to eliminate the ...
Clinically relevant drug-drug interactions (DDI) are a serious concern for any new drug development project. To better support capturing the multiple mechanisms of DDI potential using primary hepatocytes, we now offer Interaction Qualified Human ...
based inTel Aviv, ISRAEL
The volume of human molecular data is growing exponentially, but our analytic capabilities are growing linearly, at best. Humans alone cannot process all this data. What’s needed is a technology capable of digesting, organizing and making sense of ...
The first model to map and compare treatments, patient groups and disease mechanisms. ...